Organogenesis Holdings Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024; filed May 9, 2024. Organogenesis is a regenerative medicine company serving Advanced Wound Care and Surgical & Sports Medicine markets. Amounts below are in U.S. dollars; financial statement figures are in millions unless noted.
Financial performance and position
| Metric | Q1 2024 | Q1 2023 / prior period |
|---|---|---|
| Net revenue | $110.0 | $107.6; up 2% |
| Advanced Wound Care revenue | $103.9 | $100.9; up 3% |
| Surgical & Sports Medicine revenue | $6.1 | $6.7; down 9% |
| Gross profit / gross margin | $81.3 / 73.9% | $81.0 / 75.3% |
| Operating expenses | $85.1 | $85.0 |
| Operating loss | $(3.9) | $(4.0) |
| Net loss | $(2.1); $(0.02) per share | $(3.0); $(0.02) per share |
| Adjusted EBITDA, non-GAAP | $2.6 | $3.8 |
| Cash used in operating activities | $(10.2) | $(5.1) |
| Cash used in investing activities | $(2.2) | $(7.6) |
| Cash used in financing activities | $(2.6) | $(1.2) |
At March 31, cash and cash equivalents were $88.6, restricted cash $0.7, working capital $144.4, and total assets $458.5. Term-loan debt was $65.2 gross ($64.9 net of discount and issuance costs); the $125.0 revolving facility was undrawn and available. The term loan carried a 7.64% rate and matures August 2026, with $50.6 of principal due at maturity. The company reported compliance with credit-agreement covenants. Management said cash, working capital, revolving availability, and expected operating cash flows should fund operations, capital expenditures, and debt service for at least 12 months beyond the filing date.
Material changes and management commentary
- Revenue growth came from Advanced Wound Care sales to existing and new customers; Surgical & Sports Medicine declined primarily because of customer purchasing patterns.
- Cost of goods sold rose 8%, faster than revenue, reflecting higher volume and product mix. Gross profit dollars were nearly flat, while gross margin declined to approximately 73.9% from 75.3%.
- R&D expense rose 14% to $12.8, primarily for clinical research and trials, including ReNu, and BLA efforts. SG&A fell 2% to $72.3, as lower headcount costs and absence of prior-year severance were partly offset by higher royalties. Royalty expense was $4.9 versus $1.4 a year earlier.
- Operating cash use increased to $10.2, driven in part by a $15.1 increase in accounts receivable and other working-capital uses. Receivables, net, rose to $96.1 from $82.0 at year-end.
- Inventory obsolescence charges increased to $2.5 from $1.4. The company attributed the increase in cost of goods sold partly to volume and mix.
- In May 2024, after quarter-end, the company announced positive top-line Phase 3 ReNu results, reporting a statistically significant reduction in knee osteoarthritis pain at six months versus control; full analysis was expected later in May.
Outlook, risks, contingencies, and unusual items
- Medicare coverage: Seven Medicare Administrative Contractors published proposed LCDs on April 25, 2024, classifying PuraPly, Novachor, TransCyte, NuShield, and CYGNUS as non-covered for DFUs and VLUs. Affinity, Apligraf, and Dermagraft remained covered in the proposals. Final coverage was unresolved; the company warned that non-coverage could materially adversely affect utilization and revenue. Earlier proposed LCDs from three contractors were withdrawn in September 2023.
- Dermagraft: Manufacturing was suspended in Q4 2021 and sales in Q2 2022. The company plans to move manufacturing to a new facility or a third party, and expects customers to substitute Apligraf; failure to realize savings or substitution could harm results.
- Vivex agreement: The company licensed CYGNUS Dual and Matrix in November 2023 and exercised its VIA option in March 2024. It recorded a $2.5 milestone accrual and a $2.5 VIA option accrual; the VIA payment was made in April 2024. The agreement also includes product royalties and runs initially through December 2026.
- Controls: Management concluded disclosure controls and internal control over financial reporting were ineffective at March 31, 2024 because of a continuing material weakness involving IT general controls and segregation of duties. Remediation includes a company-wide ERP implementation expected to continue through 2024 and 2025, added controls, and external testing support.
- Legal matter: A securities class action was dismissed with prejudice on March 29, 2024; plaintiffs did not appeal. Management said other claims were not expected to have a material effect.
- The company reported no material changes to its previously disclosed risk factors other than the proposed Medicare LCD risk. It also disclosed a $2.5 accrued Vivex milestone and $2.5 VIA option payment, and continuing related-party lease obligations. No formal full-year revenue or earnings guidance was provided in the supplied filing text.
Key facts for investors to verify
- Final Medicare LCD decisions, effective dates, and product-level coverage and utilization impacts.
- ReNu full Phase 3 results and any subsequent regulatory or commercialization plans.
- Dermagraft manufacturing transition timing, associated costs, and whether customers substitute Apligraf.
- Receivables growth, credit-loss allowance, inventory reserves, and cash conversion in subsequent quarters.
- Progress and testing results for remediation of the material weakness and ERP implementation.
- Debt amortization, the August 2026 maturity payment, covenant compliance, and actual use of revolving capacity.